stockrow
Monday 9 November 2026
Export MSLE’s income statement to Excel — free account
Satellos Bioscience Inc.
MSLE- EPS
- −42.5%
- Free cash flow
- −65.7%
Quarter to June 2026, against a year earlier
7.19
0.84
+13.23%
Follow MSLE
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | (1) | (1) | (1) | (1) | (1) | (12) | (9) | (12) | (21) | (25) | (34) | +40.9% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (1) | (1) | (1) | (1) | (1) | (12) | (9) | (12) | (21) | (25) | (35) | +41.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (3.20) | (2.71) | (3.70) | (2.86) | (1.73) | (6.12) | (3.00) | (1.68) | (2.16) | (1.70) | (1.98) | (6.8%) | ||||||
| Cash flow | (2.86) | (2.68) | (2.40) | (3.31) | (1.06) | (2.00) | (1.48) | (1.49) | (1.91) | (1.62) | (1.39) | (6.1%) | ||||||
| Capex | (0.01) | 0.00 | (0.01) | (0.01) | 0.00 | 0.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (28.8%) | ||||||
| Free cash flow | (2.87) | (2.68) | (2.41) | (3.32) | (1.06) | (1.31) | (1.48) | (1.49) | (1.91) | (1.62) | (1.39) | (6.2%) | ||||||
| Book value | 4.97 | 2.38 | (1.36) | 0.98 | (0.87) | 4.17 | 0.87 | 4.19 | 4.93 | 1.90 | 2.88 | (10.1%) | ||||||
| Shares, m | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 7 | 10 | 15 | 17 | +51.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | (1) | (2) | (1) | (4) | (4) | (11) | (18) | (24) | (29) | +42.0% | |||||
| Capex | 0 | — | 0 | 0 | — | 1 | 0 | 0 | 0 | 0 | 0 | +8.0% | ||||||
| Free cash flow | (1) | (1) | (1) | (2) | (1) | (3) | (4) | (11) | (18) | (24) | (29) | +41.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 2 | 1 | 0 | 0 | (1) | 3 | 0 | 27 | 47 | 28 | 60 | +36.2% | |||||
| Net debt | (2) | (1) | 0 | (1) | 0 | (4) | (1) | (29) | (49) | (28) | (62) | +35.6% | ||||||
| Shareholders’ equity | 2 | 1 | 0 | 0 | (1) | 8 | 3 | 30 | 47 | 28 | 60 | +36.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (48.32) | (65.54) | (217.65) | (235.05) | (146.71) | (236.78) | (117.61) | (62.64) | (49.39) | (60.20) | (64.76) | (11.9) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (64.98) | (367.58) | (955.67) | 0.00 | (22,347.13) | 0.00 | (22,347.1) pt | ||||||
| ROE | (50.35) | (73.81) | (722.59) | (14,680.40) | 3,572.03 | (317.08) | (159.00) | (71.94) | (53.39) | (66.37) | (70.45) | (16.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
Negative figures in brackets.
estimates
Latest quarter Jun 2021 · fundamentals updated 26 Oct 2026
Satellos Bioscience Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MSLE Satellos Bioscience Inc. | $152.6M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | |
| MGNX MacroGenics, Inc. | $148.4M | — (loss-making) | — (loss-making) | +47.62% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| YARW Yarrow Bioscience, Inc | $147.2M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| NGEN NervGen Pharma Corp. | $143.1M | — (loss-making) | — | — | n/m | −48.10% (below 0%: shrinking) | — | 0.00% | Compare |
| VRXA Veraxa Biotech AG | $140.4M | — | — | — | — | — | — | — | Compare |
| CMPX Compass Therapeutics, Inc. | $136.7M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CUE Cue Biopharma, Inc. | $136.1M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TARA Protara Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADAG Adagene Inc. Sponsored ADR | $134.3M | — | — (loss-making) | — | — | −11.08% (below 0%: shrinking) | — | — | Compare |
| Median of peers | $138.5M | — | — | +47.62% | — | −26.05% | 100.00% | (21.09%) |